Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialHoward West, Federico Cappuzzo, Henry Jacob Conter et al.|The Lancet Oncology|2019Cited by 1.7k
IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLCFederico Cappuzzo, Howard West, Michael McCleod et al.|Annals of Oncology|2018Cited by 58
nab-paclitaxel (nab-P) + carboplatin (C) induction therapy in patients (Pts) with squamous (SCC) NSCLC: Interim safety results from the phase 3 ABOUND.sqm studyE. Kim, Davey B. Daniel, Jeanna Knoble et al.|Annals of Oncology|2016Cited by 0